FCHO2

Across TCGA pan-cancer cohorts, FCHO2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of FCHO2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where FCHO2 RNA is repressed in tumor relative to normal tissue. In most cancer types FCHO2 is over-expressed in tumor, although a few such as LUSC and HNSC show the opposite, repressed pattern.

LUSC, HNSC, and UCEC are the cancer types where FCHO2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FCHO2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Female	All	−1.402	<.001	8	view →
HNSC	Male	II,III,IV	−0.817	<.001	8	view →
UCEC	All	All	−1.103	<.001	6	view →
KICH	Female	All	−1.280	<.001	5	view →
READ	All	All	−0.857	<.001	5	view →
COAD	All	All	−0.559	<.001	4	view →
LIHC	All	All	+0.451	<.001	4	view →
CHOL	All	All	+1.428	<.001	3	view →
KIRC	All	All	+0.333	.001	2	view →
BRCA	Female	All	−0.220	.009	2	view →
LUAD	Female	II,III,IV	−0.506	.010	1	view →
THCA	Male	All	+0.244	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

FCHO2–LUSC

Open the LUSC breakdown →